Acute Ischemic Stroke
Conditions
Interventions
Experimental Group:1. Qilian Detoxifying and Brain-Protecting Formula: Ingredients: 30g of Radix Astragali, 6g of Coptis, 10g of Acorus tatarinowii, 15g of Paeonia rubra, 9g of Earthworm, 9g of Impera
Control Group:Conventional Western medical treatment is carried out in accordance with the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023," which mainly includes: an
Sponsors
Beijing University of Chinese Medicine Dongzhimen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for apoplexy in traditional Chinese medicine and acute ischemic stroke in Western medicine; (2) Patient age is between 18 and 80 years (inclusive), and written informed consent is obtained from the patient and their family; (3) Onset of ischemic stroke is within 72 hours; (4) NIHSS score is between 4 and 18 (inclusive); (5) Syndrome is classified as Qi deficiency with phlegm-heat; (6) The subject has given informed consent and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Exclude diseases such as intracranial hemorrhage, intracranial infections, intracranial tumors, moyamoya disease, vasculitis, and carotid artery dissection, which may cause significant narrowing or occlusion of large vessels; (2) Patients with posterior circulation ischemic stroke confirmed by imaging studies; (3) Patients with a baseline modified Rankin Scale (mRS) score = 2 points prior to the current episode; (4) Patients who received thrombolytic therapy within = 24 hours; (5) Patients with mental abnormalities or consciousness disorders who are unable to cooperate with examinations or physical assessments; (6) Patients who were unable to complete cranial MRI or other relevant tests due to various reasons, or who refused related investigations or follow-ups; (7) Patients with severe diseases of the heart, lungs, liver, kidneys, or other major organs; (8) Pregnant women, those planning pregnancy, or women in the lactation period; (9) Patients currently participating in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS score;Traditional Chinese Medicine (TCM) Syndrome Scale;BI Score; | — |
Countries
China
Contacts
Public ContactChen Xing, Cui Fangyuan
Beijing University of Chinese Medicine Dongzhimen Hospital
Outcome results
None listed